U.S. Hotel and Resort REITs Stock News

Sensata Technologies Holding (ST) recently introduced its FaultBreak contactor, a high voltage switching and protection device for electric vehicles that combines fuse and contactor functions to cut system complexity, weight, and cost. See our latest analysis for Sensata Technologies Holding. The FaultBreak launch comes as Sensata’s share price sits at US$34.27, with a recent 7 day share price return of 3.91% and a 30 day share price return of 7.93%. The 1 year total shareholder return of...

If you are wondering whether Coca-Cola FEMSA. de is still offering fair value at around US$97.16 per share, this article will walk through what the current price might be implying about the business. The stock has seen mixed recent returns, with a 6.8% decline over the past week and a 13.7% decline over the last month, set against longer term returns of 2.4% year to date, 13.6% over 1 year, 45.3% over 3 years and 154.2% over 5 years. Recent attention around Coca-Cola FEMSA. de has centered...

If you are wondering whether Hyatt Hotels' share price still reflects good value, or if you are late to the story, this article will walk through what the numbers say about the stock today. Hyatt last closed at US$139.30, with a 6.9% decline over 7 days and a 17.4% decline over 30 days, while the stock shows a 14.4% return over 1 year, 33.0% over 3 years and 62.2% over 5 years. Recent headlines around Hyatt have focused on its ongoing position as a global hotel operator and the broader...

JD.com (JD) just reported mixed fourth quarter and full year 2025 results, with revenue growth but a quarterly net loss as heavier marketing, R&D and new business spending, including food delivery, weighed on margins. See our latest analysis for JD.com. JD.com shares have been choppy, with a 7 day share price return of 4.77% offset against a 1 year total shareholder return decline of 32.49%. This suggests recent momentum is building after a tougher stretch for longer term holders. If JD.com's...

Dyne Therapeutics plans to submit an accelerated application for its Duchenne muscular dystrophy drug, targeting a potential commercial launch in early 2027. The company has completed enrollment in its Phase 1/2 trial in myotonic dystrophy type 1 and started a Phase 3 trial for DYNE-101 in DM1. New long term DELIVER trial data report meaningful improvements in lung and cardiac function in patients with Duchenne muscular dystrophy. For investors watching NasdaqGS:DYN, these clinical and...

If you are wondering whether Sally Beauty Holdings is still worth your attention at around US$14.54 per share, this article walks through what that price could mean for value focused investors. The stock is roughly flat year to date with a 0.3% return. However, the 59.4% return over the past year, alongside shorter term moves of a 1.7% decline over 7 days and a 4.5% decline over 30 days, suggests sentiment has shifted more than once recently. Recent coverage has focused on Sally Beauty...

Event context and recent share performance IHS Holding (NYSE:IHS) did not report a fresh headline event today, but the stock’s recent moves and fundamentals give you a few concrete markers to work with as you think about its role in your portfolio. See our latest analysis for IHS Holding. With the share price at US$8.20, IHS Holding has seen a 90 day share price return of 11.56% and a 1 year total shareholder return of 116.93%. This suggests momentum has been building over the past year,...

In early March 2026, Hormel Foods’ SPAM brand and Bachan’s launched a limited-edition SPAM Japanese Barbecue Sauce Flavored product, combining SPAM with Bachan’s Original Japanese Barbecue Sauce to celebrate Asian American food culture and fan-inspired recipes. This fan-driven collaboration highlights how Hormel is experimenting with culturally rooted flavors and social media–inspired products, even as investors weigh concerns about the company’s high dividend payout ratio relative to...

If you are trying to work out whether Lindsay's share price lines up with its underlying value, you are not alone. This article is built to help you unpack that question step by step. Lindsay's shares last closed at US$125.38, with returns of 3.5% year to date and declines of 3.3% over the past week, 6.9% over the past month, 2.8% over the past year, 6.0% over three years and 20.4% over five years. These figures may influence how investors are thinking about both growth potential and...

RTX (RTX) is back in focus after its Raytheon business completed a $115 million, 26,000 square foot expansion of the Redstone Missile Integration Facility, increasing integration and delivery capacity by more than 50%. See our latest analysis for RTX. The latest missile facility expansion comes as RTX shares trade at US$204.52, with a 90 day share price return of 14.47% and a 1 year total shareholder return of 59.99%. This suggests that momentum has been building around the broader defense...

Earlier this week, Celcuity announced that the Journal of Clinical Oncology published Phase 3 VIKTORIA-1 results showing the gedatolisib triplet and doublet regimens substantially reduced the risk of disease progression or death versus fulvestrant alone in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer after CDK4/6 inhibitor and aromatase inhibitor therapy. The data highlight gedatolisib’s differentiated, multi-target PAM pathway inhibition, which produced a 7.3-month...

Western Midstream Partners (WES) is back in focus after revamping its long term agreement with Occidental, shifting to fixed fees with minimum volume commitments through 2035 and receiving a large share transfer in return. See our latest analysis for Western Midstream Partners. Against that backdrop, Western Midstream Partners' share price is at US$40.82, with a 90 day share price return of 3.58% and a year to date gain of 2.77%. Its 1 year total shareholder return of 9.28% sits on top of...

Earlier this week, Diodes Incorporated expanded its automotive power management lineup by launching the AL8859Q, a multi-phase SPI boost controller designed for advanced, functionally safe headlight and broader vehicle power systems, alongside a standard-compliance AL8859 version for industrial and consumer use. By combining high efficiency, tight voltage accuracy, EMI-friendly spread-spectrum modulation, and extensive diagnostics in a compact package priced at US$0.60 for 10,000-piece...

Why Sonoco Products is on investors’ radar Sonoco Products (SON) has drawn fresh attention after recent share price moves, with the stock closing at $53.32 as investors reassess its long history in packaging across consumer and industrial markets. See our latest analysis for Sonoco Products. The recent 1 day share price return of 1.1% builds on a 25.6% 90 day share price return and a 22.3% 1 year total shareholder return, suggesting momentum has been improving after a quieter multi year...

Trust Platform expansion sharpens focus on security driven demand Microchip Technology (MCHP) has extended its Trust Platform with the TA101 TrustFLEX secure authentication IC and TA101 TrustMANAGER service, targeting tighter cybersecurity rules in industrial and automotive markets. These additions are built for products subject to the EU Cyber Resilience Act and for software defined vehicle architectures, giving manufacturers hardware based authentication, lifecycle key management and...

Government contract wins put Reliance (RS) in focus Reliance (RS) drew investor attention after subsidiary AMI Metals secured two sizeable U.S. government contracts, one tied to border wall steel and logistics and another supporting Lockheed Martin’s F-35 aluminum plate processing. See our latest analysis for Reliance. Despite the AMI Metals contract wins and recent broker commentary, Reliance’s share price has pulled back with a 17.5% 1 month share price return. However, the 1 year total...

Why Fair Isaac is back in focus Fair Isaac (FICO) has jumped back onto investors’ radar after two linked developments, rising pressure from rival credit scores in U.S. mortgages and a fresh US$1b senior notes issuance. Together, these moves have raised questions about how secure FICO’s core Scores business really is and how management is choosing to fund the next phase of the company’s evolution. See our latest analysis for Fair Isaac. FICO’s share price has been under pressure for several...

Fluence Energy (FLNC) is back in focus after a bullish SEIA and Wood Mackenzie report pointed to strong U.S. solar and storage installations, with solar projected to lead new grid capacity additions in 2025. See our latest analysis for Fluence Energy. Fluence Energy’s recent moves reflect a mixed picture, with a 10.83% 7 day share price return and a 26.18% 90 day share price decline, yet a very large 1 year total shareholder return suggests longer term momentum has been stronger than the...

In recent days, Danaher has come under pressure after its US$9.90 billion Masimo acquisition raised questions about higher debt levels, integration risks, and a more cautious full-year 2026 outlook amid sector headwinds. At the same time, a law firm has begun investigating potential fiduciary duty breaches by certain officers and directors, while a Danaher subsidiary, IDBS, received an industry award for biopharma digitalisation in Asia-Pacific. These developments highlight how Danaher’s...

In recent updates, Landstar System expanded its heavy haul and Mexico cross-border services while maintaining dividends, share repurchases, and a lower long-term debt load. This combination of operational expansion and financial conservatism contrasts with softer freight demand and capacity imbalances that have led analysts to trim earnings expectations. Now we’ll explore how analysts’ cautious earnings revisions, despite Landstar’s heavy haul and Mexico expansion, reshape the company’s...

If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about the business. The stock has seen mixed returns, with a 5.7% decline over the last 7 days and a 19.1% decline over the last 30 days, set against a 27.2% return over 3 years and 9.6% over 1 year. These figures can change how investors view both its growth prospects and risk. Recent coverage of...

Kadant stock moves: how recent returns stack up for long term holders Kadant (KAI) has seen mixed share performance recently, with a 5.5% decline over the past day and about 9.3% over the past month, while the past 3 months show a 3.9% gain. See our latest analysis for Kadant. Zooming out from the recent pullback, Kadant’s 1-day and 30-day share price returns of 5.5% and 9.3% declines contrast with a 6% year to date gain and a 56.2% three year total shareholder return. This suggests momentum...

Earlier this month, Stewart Information Services’ board declared a first-quarter 2026 cash dividend of US$0.525 per share, while director Bradley C. Allen Jr. purchased 1,000 shares on March 10, 2026, adding to his accumulated insider buying over the past year. Together, the sustained dividend and director share purchase highlight active insider participation and a board signaling confidence in the company’s cash generation and operations. Next, we’ll examine how the reaffirmed dividend...

In recent days, analysts at Canaccord Genuity and Stifel reiterated positive views on Artivion, highlighting the aortic disease pipeline and particularly the NEXUS stent graft system after one-year trial data showed strong sealing and low endoleak rates, with physicians indicating plans to adopt the device if it receives FDA approval. This combination of supportive clinical evidence and physician interest underscores how Artivion’s pipeline products could strengthen its position in treating...